Cystic fibrosis pulmonary guidelines: Chronic medications for maintenance of lung health

American Journal of Respiratory and Critical Care Medicine

Volumn 176, Issue 10, 2007, Pages 957-969

  Flume, Patrick A ^a,h   O'Sullivan, Brian P ^b   Robinson, Karen A ^c   Goss, Christopher H ^d   Mogayzel Jr , Peter J ^c   Willey Courand, Donna Beth ^e   Bujan, Janet ^f   Finder, Jonathan ^g   Lester, Mary ^h   Quittell, Lynne ⁱ   Rosenblatt, Randall ^j   Vender, Robert L ^k   Hazle, Leslie ^l   Sabadosa, Kathy ^m   Marshall, Bruce ^l  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f TEXAS CHILDREN S HOSPITAL   (United States)

^g UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^h MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

ⁱ Och Spine at New York Presbyterian Hospitals   (United States)

^j UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^k PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^l CYSTIC FIBROSIS FOUNDATION   (United States)

^m DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

more..

Author keywords

Antibiotics; Antiinflammatory agents; Bronchodilators; Hypertonic; Mucolytics; Saline solution

Indexed keywords

ACETYLCYSTEINE; ANTIBIOTIC AGENT; AZITHROMYCIN; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CEFALEXIN; CEFTAZIDIME; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLARITHROMYCIN; COLISTIN; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DORNASE ALFA; FLUTICASONE; GENTAMICIN; IBUPROFEN; ICOSAPENTAENOIC ACID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MACROLIDE; MONTELUKAST; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PREDNISONE; SALBUTAMOL; SODIUM CHLORIDE; TOBRAMYCIN; UNINDEXED DRUG; ZAFIRLUKAST;

AEROSOL; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ARTICLE; BRONCHOSPASM; CATARACT; CLINICAL TRIAL; COCHRANE LIBRARY; CORTICOSTEROID THERAPY; COUGHING; CYSTIC FIBROSIS; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FORCED EXPIRATORY VOLUME; GLUCOSE METABOLISM; GRAM NEGATIVE INFECTION; GROUPS BY AGE; GROWTH RETARDATION; HUMAN; LONG TERM CARE; LUNG DISEASE; LUNG FUNCTION; LUNG INFECTION; LUNG INSUFFICIENCY; NAUSEA; PNEUMONIA; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; STAPHYLOCOCCUS INFECTION; SURVIVAL; SYSTEMATIC REVIEW; THROAT DISEASE; TINNITUS; UNSPECIFIED SIDE EFFECT; VOICE CHANGE; WHEEZING;

ANTI-ASTHMATIC AGENTS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; CHILD; CYSTIC FIBROSIS; DEOXYRIBONUCLEASE I; HUMANS;

EID: 36248953255     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200705-664OC     Document Type: Article

References (112)

1. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry: 2005 Annual data report to the center directors. Bethesda, MD: Cystic Fibrosis Foundation; 2006.
2. Cystic Fibrosis Foundation. Concepts in Care consensus conference on use of aerosolized antibiotics in CF patients, September 22-23, 1997. Bethesda, MD: Cystic Fibrosis Foundation; 1997. Volume VIII, pp. 1-19.
3. Ramsey BW, Dorkin HL. Consensus conference: practical applications of Pulmozyme. Pediatr Pulmonol 1994;17:404-408.
4. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, Atkins D; Methods Word Group, Third US Preventive Services Task Force. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med 2001;20(Suppl 3):21-35. Article reproduced on Agency for Healthcare Research and Quality website. Rockville, MD: AHRQ, Available from: http://www.ahrq.gov/clinic/ajpmsuppl/harris1.htm (cited 2007 Sep).
5. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002;34:91-100.
6. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev KM, Borowitz D, Bowman CM, Marshall BC, et al.; Cystic Fibrosis Inhaled Tobramycin Study Group. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999;340:23-30.
7. MacLusky IB, Gold R, Corey M, Levison H. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonol 1989;7:42-48.
8. Ramsey BW, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Kravitz RM, Schidlow DV, Wilmott RW, Astley SJ, McBurnie MA, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993;328:1740-1746.
9. Wiesemann HG, Steinkamp G, Ratjen F, Bauernfeind A, Przyklenk B, Doring G, von der Hardt H. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 1998;25:88-92.
10. Ryan G, Mukhopadhyay S, Singh M. Nebulised anti-pseudomonal antibiotics for cystic fibrosis. Cochrane Database Syst Rev [serial on the Internet]. 2003 [updated 2006; accessed September 2007];3:CD001021. Available from http://www.cochrane.org/reviews/clibintro.htm
11. Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovey M, Hiatt P, et al.; Cystic Fibrosis Therapeutics Development Network Study Group. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003;167:841-849.
12. Murphy TD, Anbar RD, Lester LA, Nasr SZ, Nickerson B, VanDevanter DR, Colin AA. Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatr Pulmonol 2004;38:314-320.
13. Jensen T, Pedersen SS, Garne S, Heilmann C, Høiby N, Koch C. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 1987;19:831-838.
14. Hodson ME, Gallagher CG, Govan JRW. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 2002;20:658-664.
15. Kun P, Landau LI, Phelan PD. Nebulized gentamicin in children and adolescents with cystic fibrosis. Aust Paediatr J 1984;20:43-45.
16. Stead RJ, Hodson ME, Batten JC. Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa. Br J Dis Chest 1987;81:272-279.
17. Cimmino M, Nardone M, Cavaliere M, Plantulli A, Sepe A, Esposito V, Mazzarella G, Raia V. Dornase alfa as postoperative therapy in cystic fibrosis sinonasal disease. Arch Otolaryngol Head Neck Surg 2005;131:1097-1101.
18. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME; Pulmozyme Study Group. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994;331:637-642.
19. Grasemann H, Lax H, Treseler JW, Colin AA. Dornase alpha and exhaled NO in cystic fibrosis. Pediatr Pulmonol 2004;38:379-385.
20. McCoy K, Hamilton S, Johnson C. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Chest 1996;110:889-895.
21. Furuya MEY, Lezana-Fernández JL, Vargas MH, Hernández- Sierra JF, Ramírez-Figueroa JL. Efficacy of human recombinant DNase in pediatric patients with cystic fibrosis. Arch Med Res 2001;32:30-34.
22. Laube BL, Auci RM, Shields DE, Christiansen DH, Lucas MK, Fuchs HJ, Rosenstein BJ. Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis. Am J Respir Crit Care Med 1996;153:752-760.
23. Ramsey BW, Astley SJ, Aitken ML, Burke W, Colin AA, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Schidlow DV, et al. Efficacy and safety of short-term administration of aerosolised recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis 1993;148:145-151.
24. Ranasinha C, Assoufi B, Shak S, Christiansen D, Fuchs H, Empey D, Geddes D, Hodson M. Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis. Lancet 1993;342:199-202.
25. Shah PL, Scott SF, Knight RA, Marriott C, Ranasinha C, Hodson ME. In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis. Thorax 1996;51:119-125.
26. Shah PI, Bush A, Canny GJ, Colin AA, Fuchs HJ, Geddes DM, Johnson CAC, Light MC, Scott SF, Tullis DE, et al. Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment. Eur Respir J 1995;8:954-958.
27. Robinson M, Hemming AL, Moriarty C, Eberl S, Bye PTP. Effect of a short course of rhDNase on cough and mucociliary clearance in patients with cystic fibrosis. Pediatr Pulmonol 2000;30:16-24.
28. Wilmott RW, Amin RS, Colin AA, DeVault A, Dozor AJ, Eigen H, Johnson C, Lester LA, McCoy K, McKean LP, et al. Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations. Am J Respir Crit Care Med 1996;153:1914-1917.
29. Jones AP, Wallis CE, Kearney CE. Recombinant human deoxyribonuclease for cystic fibrosis. Cochrane Database Syst Rev [serial on the Internet]. 2003 [updated 2005; accessed September 2007];3:CD001127. Available from http://www.cochrane.org/reviews/clibintro.htm
30. Quan JM, Tiddens HAWM, Sy JP, McKenzie SG, Montgomery MD, Robinson PJ, Wohl MEB, Konstan MW. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 2001;139:813-820.
31. Robinson TE, Goris ML, Zhu HJ, Chen X, Bhise P, Sheikh F, Moss RB. Dornase alfa reduces air trapping in children with mild cystic fibrosis. Chest 2005;128:2327-2335.
32. Nasr SZ, Kuhns LR, Brown RW, Hurwitz ME, Sanders GM, Strouse PJ. Use of computerized tomography and chest x-rays in evaluating efficacy of aerosolized recombinant human DNase in cystic fibrosis patients younger than age 5 years: a preliminary study. Pediatr Pulmonol 2001;31:377-382.
33. Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006;354:241-250.
34. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, Belousova EG, Xuan W, Bye PT. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354:229-240.
35. Eng PA, Morton J, Douglass JA, Riedler J, Wilson J, Robertson CF. Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatr Pulmonol 1996;21:77-83.
36. Ballmann M, von der Hardt H. Hypertonic saline and recombinant human DNase: a randomised crossover pilot study in patients with cystic fibrosis. J Cyst Fibros 2002;1:35-37.
37. Suri R, Grieve R, Normand C, Metcalfe C, Thompson S, Wallis C, Bush A. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax 2002;57:841-846.
38. Wark PA, McDonald V, Jones AP. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev [serial on the Internet]. 2005 [accessed September 2007];3:CD001506. Available from http://www.cochrane.org/ reviews/clibintro.htm
39. Birrer P, McElvaney NG, Rudeberg A, Sommer CW, Liechti-Gallati S, Kraemer R, Hubbard R, Crystal RG. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med 1994;150:207-213.
40. Konstan MW, Hilliard KA, Norvell TM, Berger M. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 1994;150:448-454.
41. Balfour-Lynn IM, Lees B, Hall P, Phillips G, Khan M, Flather M, Elborn JS. Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis. Am J Respir Crit Care Med 2006;173:1356-1362.
42. Balfour-Lynn IM, Klein NJ, Dinwiddie R. Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis. Arch Dis Child 1997;77:124-130.
43. Nikolaizik WH, Schöni MH. Pilot study to assess the effect of inhaled corticosteroids on lung function in patients with cystic fibrosis. J Pediatr 1996;128:271-274.
44. Schiotz PO, Jorgensen M, Flensborg EW, Faero O, Husby S, Hoiby N, Jacobsen SV, Nielsen H, Svehag SE. Chronic Pseudomonas aeruginosa lung infection in cystic fibrosis: a longitudinal study of immune complex activity and inflammatory response in sputum sol-phase of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infections: influence of local steroid treatment. Acta Paediatr Scand 1983;72:283-287.
45. Dauletbaev N, Viel K, Behr J, Loitsch S, Buhl R, Wagner TOF, Bargon J. Effects of short-term inhaled fluticasone on oxidative burst of sputum cells in cystic fibrosis patients. Eur Respir J 1999;14:1150-1155.
46. Bisgaard H, Pedersen SS, Nielsen KG, Skov M, Laursen EM, Kronborg G, Reimert CM, Høiby N, Koch C. Controlled trial of inhaled budesonide in patients with cystic fibrosis and chronic bronchopulmonary Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 1997;156:1190-1196.
47. van Haren EHJ, Lammers J-WJ, Festen J, Heijerman HGM, Groot CAR, van Herwaarden CLA. The effects of the inhaled corticosteroid budesonide on lung function and bronchial hyperresponsiveness in adult patients with cystic fibrosis. Respir Med 1995;89:209-214.
48. Balfour-Lynn I, Walters S, Dezateux C. Inhaled corticosteroids for cystic fibrosis. Cochrane Database Syst Rev [serial on the Internet]. 2000 [updated 2006; accessed September 2007];2:CD001915. Available from http://www.cochrane.org/reviews/clibintro.htm
49. Auerbach HS, Williams M, Kirkpatrick JA, Colten HR. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet 1985;2:686-688.
50. Greally P, Hussain MJ, Vergani D, Price JF. Interleukin-1α, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Arch Dis Child 1994;71:35-39.
51. Eigen H, Rosenstein BJ, FitzSimmons S, Schidlow DV; Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. J Pediatr 1995;126:515-523.
52. Cheng K, Ashby D, Smyth R. Oral steroids for cystic fibrosis. Cochrane Database Syst Rev [serial on the Internet]. 2000 [updated 2006; accessed September 2007];2:CD000407. Available from http://www.cochrane.org/reviews/ clibintro.htm
53. Pantin CFA, Stead RJ, Hodson ME, Batten JC. Prednisolone in the treatment of airflow obstruction in adults with cystic fibrosis. Thorax 1986;41:34-38.
54. Konstan MW, Hoppel CL, Chai B, Davis PB. Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. J Pediatr 1991;118:956-964.
55. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995;332:848-854.
56. Sordelli DO, Macri CN, Maillie AJ, Cerquetti MC. A preliminary study on the effect of anti-inflammatory treatment in cystic fibrosis patients with Pseudomonas aeruginosa lung infection. Int J Immunopathol Pharmacol 1994;7:109-117.
57. Lands LC, Dezateux C, Crighton A. Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis. Cochrane Database Syst Rev [serial on the Internet]. 1999 [updated 2005; accessed September 2007];2:CD001505. Available from http://www.cochrane.org/reviews/clibintro.htm
58. Konstan MW, Krenicky JE, Finney MR, Kirchner HL, Hilliard KA, Hilliard JB, Davis PB, Hoppel CL. Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects. J Pharmacol Exp Ther 2003;306:1086-1091.
59. Stelmach I, Korzeniewska A, Smejda K, Jarosz I, Stelmach W. [Effect of montelukast on lung function and clinical symptoms in patients with cystic fibrosis]. Pneumonol Alergol Pol 2004;72:85-89.
60. Conway SP, Etherington C, Peckham DG, Whitehead A. A pilot study of zafirlukast as an anti-inflammatory agent in the treatment of adults with cystic fibrosis. J Cyst Fibros 2003;2:25-28.
61. 4. Lancet 1993;342:465-469.
62. Mitchell I. Sodium cromoglycate-induced changes in the dose-response curve of inhaled methacholine in cystic fibrosis. Ann Allergy 1985;54:233-235.
63. Chua HL, Walker SL, LeSouef PN, Sly PD. Comparison of efficacy of salbutamol and sodium cromoglycate in the prevention of ticarcillin-induced bronchoconstriction. Pediatr Pulmonol 1993;16:311-315.
64. Sivan Y, Arce P, Eigen H, Nickerson BG, Newth CJ. A double-blind, randomized study of sodium cromoglycate versus placebo in patients with cystic fibrosis and bronchial hyperreactivity. J Allergy Clin Immunol 1990;85:649-654.
65. Koyama H, Geddes DM. Erythromycin and diffuse panbronchiolitis. Thorax 1997;52:915-918.
66. Ordoñez CL, Stulbarg M, Grundland H, Liu JT, Boushey HA. Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study. Pediatr Pulmonol 2001;32:29-37.
67. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell PW III. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003;290:1749-1756.
68. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002;57:212-216.
69. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002;360:978-984.
70. Southern KW, Barker PM, Solis A. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev [serial on the Internet]. 2004 [updated 2005; accessed September 2007];2:CD002203. Available from http://www.cochrane.org/reviews/clibintro.htm
71. Weaver LT, Green MR, Nicholson K, Mills J, Heeley ME, Kuzemko JA, Austin S, Gregory GA, Dux AE, Davis JA. Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period. Arch Dis Child 1994;70:84-89.
72. Loening-Baucke VA, Mischler E, Myers MG. A placebo-controlled trial of cephalexin therapy in the ambulatory management of patients with cystic fibrosis. J Pediatr 1979;95:630-637.
73. Stutman HR, Lieberman JM, Nussbaum E, Marks MI. Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial. J Pediatr 2002;140:299-305.
74. Beardsmore CS, Thompson JR, Williams A, McArdle EK, Gregory GA, Weaver LT, Simpson H. Pulmonary function in infants with cystic fibrosis: the effect of antibiotic treatment. Arch Dis Child 1994;71:133-137.
75. Smyth A, Walters S. Prophylactic anti-staphylococcal antibiotics for cystic fibrosis. Cochrane Database Syst Rev [serial on the Internet]. 2003 [updated 2006; accessed September 2007];3:CD001912. Available from http://www.cochrane.org/reviews/clibintro.htm
76. Halfhide C, Evans HJ, Couriel J. Inhaled bronchodilators for cystic fibrosis. Cochrane Database Syst Rev [serial on the Internet]. 2005 [accessed September 2007];4:CD003428. Available from http://www.cochrane.org/ reviews/clibintro.htm
77. Pitcher-Wilmott R, Matthew DJ, Ingram D, Tyson SL. Improvement in lung function after nebulised salbutamol and ipratropium in children with cystic fibrosis. Abstract presented at the 11th European Cystic Fibrosis Conference, Brussels, Belgium, 1982.
78. Duncan FR, Penketh ARL, Hodson ME, Batten JC. The use of bronchodilators as an adjunct to physiotherapy in adults with cystic fibrosis. Abstract presented at the 11th European Cystic Fibrosis Conference, Brussels, Belgium, 1982.
79. Avital A, Sanchez I, Chernick V. Efficacy of salbutamol and ipratropium bromide in decreasing bronchial hyperreactivity in children with cystic fibrosis. Pediatr Pulmonol 1992;13:34-37.
80. Hordvik NL, Sammut PH, Judy CG, Strizek SJ, Colombo JL. The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. Am J Respir Crit Care Med 1996;154:156-160.
81. Hordvik NL, Sammut PH, Judy CG, Colombo JL. Effectiveness and tolerability of high-dose salmeterol in cystic fibrosis. Pediatr Pulmonol 2002;34:287-296.
82. Sanchez I, Holbrow J, Chernick V. Acute bronchodilator response to a combination of β-adrenergic and anticholinergic agents in patients with cystic fibrosis. J Pediatr 1992;120:486-488.
83. Ziebach R, Pietsch-Breitfeld B, Bichler M, Busch A, Riethmuller J, Stern M. Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatr Pulmonol 2001;31:431-435.
84. Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99:1088-1092.
85. Hordvik NL, Sammut PH, Judy CG, Colombo JL. Effects of standard and high doses of salmeterol on lung function of hospitalized patients with cystic fibrosis. Pediatr Pulmonol 1999;27:43-53.
86. Konig P, Poehler J, Barbero GJ. A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatr Pulmonol 1998;25:32-36.
87. Sanchez I, De Koster J, Holbrow J, Chernick V. The effect of high doses of inhaled salbutamol and ipratropium bromide in patients with stable cystic fibrosis. Chest 1993;104:842-846.
88. Serisier DJ, Rice-McDonald G, Bowler SD, Coates AC, Breust B. β-Adrenergic agonists do not improve exercise capacity in cystic fibrosis. Pediatr Pulmonol Suppl 2000;20:305.
89. Dodd JD, Barry SC, Daly LE, Gallagher CG. Inhaled β-agonists improve lung function but not maximal exercise capacity in cystic fibrosis. J Cyst Fibros 2005;4:101-105.
90. Salvatore D, D'Andria M. Effects of salmeterol on arterial oxyhemoglobin saturations in patients with cystic fibrosis. Pediatr Pulmonol 2002;34:11-15.
91. Duijvestijn YC, Brand PL. Systematic review of N-acetylcysteine in cystic fibrosis. Acta Paediatr 1999;88:38-41.
92. Tramper-Stranders GA, Wolfs TF, Fleer A, Kimpen JL, van der Ent CK. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function. Pediatr Infect Dis J 2007;26:8-12.
93. van der Giessen LJ, de Jongste JC, Gosselink R, Hop WC, Tiddens HA. rhDNase before airway clearance therapy improves airway patency in children with CF. Pediatr Pulmonol 2007;42:624-630.
94. Fitzgerald DA, Hilton J, Jepson B, Smith L. A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis. Pediatrics 2005;116:e549-e554.
95. LiPuma JJ. Microbiological and immunologic considerations with aerosolized drug delivery. Chest 2001;120:118S-123S.
96. Lipworth BJ. Pharmacokinetics of inhaled drugs. Br J Clin Pharmacol 1996;42:697-705.
97. Clinical Practice Guidelines for Cystic Fibrosis Committee. Clinical practice guidelines for cystic fibrosis. Bethesda, MD: Cystic Fibrosis Foundation; 1997.
98. Smith AL, Ramsey BW, Hedges DL, Hack B, Williams-Warren J, Weber A, Gore EJ, Redding GJ. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr Pulmonol 1989;7:265-271.
99. Steinkamp G, Tümmler B, Gappa M, Albus A, Potel J, Döring G, von der Hardt H. Long-term tobramycin aerosol therapy in cystic fibrosis. Pediatr Pulmonol 1989;6:91-98.
100. Hubbard RC, McElvaney NG, Birrer P, Shak S, Robinson WW, Jolley C, Wu M, Chernick MS, Crystal RG. A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. N Engl J Med 1992;326:812-815.
101. Aitken ML, Burke W, McDonald G, Shak S, Montgomery AB, Smith A. Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis: a phase 1 study. JAMA 1992;267:1947-1951.
102. Eisenberg JD, Aitken ML, Dorkin HL, Harwood IR, Ramsey BW, Schidlow DV, Wilmott RW, Wohl ME, Fuchs HJ, Christiansen DH, et al. Safety of repeated intermittent courses of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. J Pediatr 1997;131:118-124.
103. Harms HK, Matouk E, Tournier G, von der Hardt H, Weller PH, Romano L, Heijerman HGM, FitzGerald MX, Richard D, Strandvik B, et al. Multicenter, open-label study of recombinant human DNase in cystic fibrosis patients with moderate lung disease. Pediatr Pulmonol 1998;26:155-161.
104. Heijerman HGM, van Rossem RN, Bakker W. Effect of rhDNase on lung function and quality of life in adult cystic fibrosis patients. Neth J Med 1995;46:293-297.
105. Ledson MJ, Tran J, Walshaw MJ. Prevalence and mechanisms of gastro-oesophageal reflux in adult cystic fibrosis patients. J R Soc Med 1998;91:7-9.
106. Shah PL, Scott SF, Geddes DM, Hodson ME. Two years experience with recombinant human DNase I in the treatment of pulmonary disease in cystic fibrosis. Respir Med 1995;89:499-502.
107. Berge MT, Wiel E, Tiddens HA, Merkus PJ, Hop WC, de Jongste JC. DNase in stable cystic fibrosis infants: a pilot study. J Cyst Fibros 2003;2:183-188.
108. Tirouvanziam R, Conrad CK, Bottiglieri T, Herzenberg LA, Moss RB. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci USA 2006;103:4628-4633.
109. Stafanger G, Garne S, Howitz P, Morkassel E, Koch C. The clinical effect and the effect on the ciliary motility of oral N-acetylcysteine in patients with cystic fibrosis and primary ciliary dyskinesia. Eur Respir J 1988;1:161-167.
110. Ratjen F, Wonne R, Posselt HG, Stover B, Hofmann D, Bender SW. A double-blind placebo controlled trial with oral ambroxol and N-acetylcysteine for mucolytic treatment in cystic fibrosis. Eur J Pediatr 1985;144:374-378.
111. Mitchell EA, Elliott RB. Controlled trial of oral N-acetylcysteine in cystic fibrosis. Aust Paediatr J 1982;18:40-42.
112. Gotz M, Kraemer R, Kerrebijn KF, Popow C. Oral acetylcysteine in cystic fibrosis: a co-operative study. Eur J Respir Dis Suppl 1980;111:122-126.